# Vaccine and Antibody Treatment of Prostate Cancer

> **NCT00113984** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **BIOLOGICAL:** PROSTVAC-V/TRICOM
- **BIOLOGICAL:** PROSTVAC-F/TRICOM
- **DRUG:** MDX-010
- **DRUG:** Sargramostim

## Key facts

- **NCT ID:** NCT00113984
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06-08
- **Primary completion:** 2008-02-01
- **Final completion:** 2011-12-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00113984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00113984, "Vaccine and Antibody Treatment of Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00113984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*